Q1 EPS Estimate for RenovoRx Raised by Analyst

RenovoRx, Inc. (NASDAQ:RNXT) – Research analysts at Ascendiant Capital Markets lifted their Q1 2027 earnings estimates for shares of RenovoRx in a research note issued to investors on Saturday, November 7th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings per share of ($0.06) for the quarter, up from their prior forecast of ($0.07). The consensus estimate for RenovoRx’s current full-year earnings is ($0.28) per share. Ascendiant Capital Markets also issued estimates for RenovoRx’s Q4 2027 earnings at ($0.03) EPS.

A number of other brokerages have also weighed in on RNXT. Wall Street Zen lowered RenovoRx from a “hold” rating to a “sell” rating in a research report on Monday. Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

RenovoRx Stock Performance

Shares of NASDAQ RNXT opened at $1.22 on Thursday. RenovoRx has a 52-week low of $0.70 and a 52-week high of $2.59. The firm has a market capitalization of $58.87 million, a price-to-earnings ratio of -3.94 and a beta of 1.12. The stock has a 50 day moving average price of $1.50 and a 200 day moving average price of $1.11.

RenovoRx (NASDAQ:RNXT) last issued its earnings results on Thursday, November 5th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative return on equity of 133.49% and a negative net margin of 469.02%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.06 million.

Hedge Funds Weigh In On RenovoRx

A hedge fund recently raised its position in RenovoRx stock. State Street Corp boosted its stake in shares of RenovoRx, Inc. (NASDAQ:RNXT) by 501.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 314,636 shares of the company’s stock after buying an additional 262,332 shares during the period. State Street Corp owned 0.65% of RenovoRx worth $491,000 as of its most recent filing with the Securities & Exchange Commission. 3.10% of the stock is currently owned by institutional investors.

About RenovoRx

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue. RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.